Drug intelligence / Profile preview

BG-T0920

Development stage: Phase 1
Lead developer: BeOne Medicines
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BG-T0920 is an investigational trispecific T-cell engager (Tri-TCE) designed to simultaneously target CD3 on T-cells and both CD22 and BAFF-R (B-cell activating factor receptor) on B-cells. Developed by BeOne Medicines (formerly BeiGene), BG-T0920 is designed to bring T-cells into close proximity with malignant B-cells, facilitating T-cell-mediated cytotoxicity. It is currently being evaluated in a Phase 1 clinical trial for the treatment of diffuse large B-cell lymphoma (DLBCL) and other aggressive B-cell malignancies.

Targets

TNFRSF13C (B-cell Activating Factor Receptor)CD22 (Cluster of Differentiation 22)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on BG-T0920.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-T0920.